Referred to the House Committee on Energy and Commerce.
The bill amends the Public Health Service Act to expand federal research and public education on endometrial cancer.
It directs the NIH Director to expand, coordinate, and intensify endometrial cancer research, communicate racial disparities (particularly between African‑American and non‑Hispanic White women), coordinate with relevant NIH institutes, and seek to ensure African‑American women are represented in NIH‑supported endometrial cancer clinical trials in proportion to incidence; it authorizes $1,000,000 per year for FY2026–2028 for NIH activities.
It also directs the CDC to develop and disseminate public information on endometrial cancer (including incidence, risk factors, treatment options, and increased risks for ethnic minority women), with materials targeted toward African‑American women, requires consultation with HRSA, and authorizes "such sums as may be necessary" for FY2026–2028 for CDC activities.
On content alone, the bill is a focused, modestly funded public-health measure that aligns with ordinary congressional activity to support disease-specific research and education; such bills often succeed or are folded into larger health or appropriations packages. Remaining barriers include the need for appropriations action to provide funds (especially for CDC, which is authorized 'such sums'), limited floor time, and possible objections to race-specific provisions or even any new federal spending. These factors lower but do not eliminate the chance of enactment.
Relative to its intended legislative type, this bill clearly establishes statutory authority for expanded endometrial cancer research and a public education program and integrates these authorities into the Public Health Service Act. It identifies responsible agencies and provides limited authorization of appropriations.
Support for advancing research and education is broadly shared, but liberals emphasize equity and stronger funding while conservatives emphasize limits on race‑targeted mandates and fiscal restraint.
Support for advancing research and education is broadly shared, but liberals emphasize equity and stronger funding while conservatives emphasize limits on race‑targeted mandates and fiscal restraint.
A mainstream liberal would likely view the bill positively as a targeted, health‑equity focused effort to address an understudied cancer and documented racial disparities in outcomes.
They would see the combination of research funding, coordination across women’s health and minority health institutes, and targeted public education for African‑American women as appropriate interventions.
They would likely note the authorization as relatively modest but appreciate the explicit focus on representation in clinical trials and on addressing drivers of disparities.
A centrist/moderate would likely view the bill as a narrowly focused, pragmatic public‑health measure that targets an identified problem — rising endometrial cancer incidence and racial disparities — and uses existing agencies to respond.
They would appreciate coordination among NIH institutes and the CDC’s role in public education, but would want clarity on costs, measurable goals, and oversight.
Centrists would generally favor the aims while looking for accountability mechanisms and evidence that the funding level is adequate.
A mainstream conservative would likely view the bill as a generally worthwhile effort to study and educate about a medical condition, but may have reservations about race‑targeted provisions, additional federal spending, and potential federal overreach into clinical trial enrollment practices.
Because the NIH dollar amounts are small and the CDC funding is undefined, some conservatives may see the bill as low‑cost and modestly acceptable; others may want clearer limits on spending and assurances that programs will be efficient and not create regulatory burdens.
Overall, reaction would be mixed but not uniformly oppositional.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a focused, modestly funded public-health measure that aligns with ordinary congressional activity to support disease-specific research and education; such bills often succeed or are folded into larger health or appropriations packages. Remaining barriers include the need for appropriations action to provide funds (especially for CDC, which is authorized 'such sums'), limited floor time, and possible objections to race-specific provisions or even any new federal spending. These factors lower but do not eliminate the chance of enactment.
The bill has not accumulated any surfaced votes yet.
Support for advancing research and education is broadly shared, but liberals emphasize equity and stronger funding while conservatives emph…
On content alone, the bill is a focused, modestly funded public-health measure that aligns with ordinary congressional activity to support…
Relative to its intended legislative type, this bill clearly establishes statutory authority for expanded endometrial cancer research and a public education program and integrates these authorities into the Public Healt…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.